Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Aringer, M; Smolen, JS; Graninger, WB.
Severe infections in plasmapheresis-treated systemic lupus erythematosus.
Arthritis Rheum. 1998; 41(3):414-420
Doi: 10.1002/1529-0131(199803)41:3<414::AID-ART6>3.0.CO;2-N
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Graninger Winfried
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: To assess the risk of infection in patients with systemic lupus erythematosus (SLE) treated with plasmapheresis in addition to intravenous (I.V.) pulse cyclophosphamide (CYC). METHODS: We searched the records of all our SLE patients for those who had undergone plasmapheresis plus I.V. CYC treatment (n = 9). Consecutive patients with similarly high SLE activity who underwent I.V. CYC therapy but not plasmapheresis were included as controls (n = 12). We evaluated both groups for severe infections, outcome, and confounding clinical variables. RESULTS: Seven of 9 plasmapheresis-treated patients had serious bacterial or viral infections, including 3 cases of cytomegalovirus infections. Among the 12 patients treated with I.V. CYC alone, only 2 had severe infections (P < 0.01). Three patients in the plasmapheresis group and none in the control group died of infections. Treatment efficacy, however, was similar for both groups. CONCLUSION: Among SLE patients treated with plasmapheresis and I.V. CYC, life-threatening bacterial and viral infections and mortality occur more frequently than among patients with similarly active SLE treated with I.V. CYC alone.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Bacterial Infections - etiology Bacterial Infections - mortality Bacterial Infections - physiopathology
- Critical Illness - mortality
- Cyclophosphamide - administration and dosage Cyclophosphamide - adverse effects Cyclophosphamide - therapeutic use
- Drug Therapy, Combination -
- Female -
- Humans -
- Immunosuppressive Agents - administration and dosage Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use
- Injections, Intravenous -
- Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - therapy
- Male -
- Plasmapheresis - adverse effects
- Prospective Studies -
- Risk Factors -
- Time Factors -
- Treatment Outcome -
- Virus Diseases - etiology Virus Diseases - mortality Virus Diseases - physiopathology